Mary L. Disis
#126,665
Most Influential Person Now
American physician-oncologist
Mary L. Disis's AcademicInfluence.com Rankings
Mary L. Disisphilosophy Degrees
Philosophy
#6567
World Rank
#9623
Historical Rank
#1540
USA Rank
Logic
#3714
World Rank
#4912
Historical Rank
#723
USA Rank
Download Badge
Philosophy
Mary L. Disis's Degrees
- Doctorate Medicine University of California, San Francisco
- Bachelors Biology University of California, San Diego
Similar Degrees You Can Earn
Why Is Mary L. Disis Influential?
(Suggest an Edit or Addition)According to Wikipedia, Mary L. "Nora" Disis is an American physician-oncologist and the editor in chief of JAMA Oncology. She was part of the scientific team who discovered that the HER2/neu molecule is a tumor-specific marker, or antigen.
Mary L. Disis's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival (2004) (4985)
- Tumor antigen-specific T helper cells in cancer immunity and immunotherapy (2005) (625)
- Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. (1994) (513)
- Toxicities of Immunotherapy for the Practitioner. (2015) (506)
- Gene expression markers of Tumor Infiltrating Leukocytes (2016) (482)
- Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. (2001) (459)
- Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. (2002) (450)
- Clinical significance of tumor-infiltrating lymphocytes in breast cancer (2016) (440)
- Immune regulation of cancer. (2010) (401)
- Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. (1999) (370)
- Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. (2016) (367)
- High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. (1997) (362)
- Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy (2002) (323)
- Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. (2009) (271)
- Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. (2011) (266)
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial (2019) (257)
- Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. (2002) (230)
- Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. (2009) (214)
- Current Landscape of Immunotherapy in Breast Cancer: A Review. (2019) (211)
- Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. (1996) (207)
- Immunity to Oncogenic Proteins (1995) (192)
- HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. (1997) (186)
- Chitosan-alginate 3D scaffolds as a mimic of the glioma tumor microenvironment. (2010) (185)
- In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. (1994) (177)
- Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy (2017) (175)
- Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines (1996) (173)
- Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs. (2012) (166)
- Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer (2000) (166)
- Use of tumour-responsive T cells as cancer treatment (2009) (164)
- Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine. (2004) (164)
- Oncogenic proteins as tumor antigens. (1996) (159)
- The Road We Must Take: Multidisciplinary Team Science (2010) (154)
- Defining the critical hurdles in cancer immunotherapy (2011) (152)
- The Human Vaccines Project: A roadmap for cancer vaccine development (2016) (151)
- IL-2 Immunotoxin Therapy Modulates Tumor-Associated Regulatory T Cells and Leads to Lasting Immune-Mediated Rejection of Breast Cancers in neu-Transgenic Mice1 (2006) (151)
- Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. (2008) (150)
- Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. (2000) (148)
- Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. (2006) (144)
- VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC (2011) (141)
- Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity. (2016) (135)
- CD4 regulatory T cells in human cancer pathogenesis (2006) (133)
- Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition1 (2006) (123)
- Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. (2000) (121)
- Maximizing the retention of antigen specific lymphocyte function after cryopreservation. (2006) (121)
- Mechanism of action of immunotherapy. (2014) (120)
- Humoral Epitope-Spreading Following Immunization with a HER-2/neu Peptide Based Vaccine in Cancer Patients (2004) (119)
- Polysaccharide Krestin Is a Novel TLR2 Agonist that Mediates Inhibition of Tumor Growth via Stimulation of CD8 T Cells and NK Cells (2010) (117)
- Immunologic biomarkers as correlates of clinical response to cancer immunotherapy (2011) (116)
- A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors (2017) (116)
- Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT (2005) (113)
- Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers (2011) (108)
- If we build it they will come: targeting the immune response to breast cancer (2019) (107)
- Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma (2014) (103)
- ELISpot for measuring human immune responses to vaccines (2011) (102)
- TNM staging in colorectal cancer: T is for T cell and M is for memory. (2011) (101)
- The Immune Landscape of Cancer. (2019) (99)
- Precancer Atlas to Drive Precision Prevention Trials. (2017) (98)
- Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial. (2015) (98)
- Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. (2002) (95)
- Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. (2003) (93)
- Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN (2016) (87)
- The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. (2008) (84)
- Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. (2005) (84)
- Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. (2000) (83)
- neu Antigen-Negative Variants Can Be Generated after neu-Specific Antibody Therapy in neu Transgenic Mice (2004) (83)
- Triple-negative breast cancer: immune modulation as the new treatment paradigm. (2015) (82)
- Treatment Failure of a TLR-7 Agonist Occurs Due to Self-Regulation of Acute Inflammation and Can Be Overcome by IL-10 Blockade (2010) (81)
- HER-2/neu oncogenic protein: issues in vaccine development. (1998) (78)
- Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. (1999) (74)
- Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor. (2009) (73)
- Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial (2017) (72)
- CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. (1995) (70)
- TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy (2011) (70)
- Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response. (2007) (68)
- Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides (2008) (67)
- Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials (2016) (67)
- Vaccination against the HER-2/neu oncogenic protein. (2002) (64)
- Evaluation of Known Oncoantibodies, HER2, p53, and Cyclin B1, in Prediagnostic Breast Cancer Sera (2012) (63)
- Naturally occurring prostate cancer antigen‐specific T cell responses of a Th1 Phenotype can be detected in patients with prostate cancer (2001) (63)
- Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy (2021) (62)
- A Multiantigen Vaccine Targeting Neu, IGFBP-2, and IGF-IR Prevents Tumor Progression in Mice with Preinvasive Breast Disease (2013) (60)
- The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. (2006) (59)
- In situ adenovirus vaccination engages T effector cells against cancer. (2009) (59)
- Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. (2008) (58)
- Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop (2019) (57)
- Pilot Study of an HLA-A2 Peptide Vaccine Using Flt3 Ligand as a Systemic Vaccine Adjuvant (2004) (56)
- Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. (2004) (56)
- Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity (2008) (56)
- Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. (2006) (53)
- Antibody to ras proteins in patients with colon cancer. (1995) (53)
- Leveraging premalignant biology for immune-based cancer prevention (2016) (52)
- Three-dimensional scaffolds to evaluate tumor associated fibroblast-mediated suppression of breast tumor specific T cells. (2013) (52)
- Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity (2016) (49)
- Clinical studies of vaccines targeting breast cancer. (2003) (49)
- HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase (2010) (48)
- Dendritic Cell–Activating Vaccine Adjuvants Differ in the Ability to Elicit Antitumor Immunity Due to an Adjuvant-Specific Induction of Immunosuppressive Cells (2012) (47)
- Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology (2009) (46)
- A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers" (2008) (46)
- Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer (2019) (45)
- Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting (2017) (45)
- Identification of T helper epitopes from prostatic acid phosphatase. (2001) (45)
- Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. (2019) (45)
- Cancer vaccines targeting the HER2/neu oncogenic protein. (2001) (44)
- Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. (2007) (44)
- Fatal Bacillus cereus sepsis following resolving neutropenic enterocolitis during the treatment of acute leukemia (2003) (42)
- Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor. (1999) (41)
- Immunotherapy in breast cancer: An introduction. (2018) (41)
- Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. (2014) (40)
- Identification of Tumor-Specific Antibodies in Patients With Breast Cancer Vaccinated With Gene-Modified Allogeneic Tumor Cells (2003) (38)
- Translational Research Working Group Developmental Pathway for Immune Response Modifiers (2008) (37)
- Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets (2020) (37)
- An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis. (2015) (37)
- Tumor Antigen–Specific T-Cell Expansion Is Greatly Facilitated by In vivo Priming (2006) (36)
- Augmenting T helper cell immunity in cancer. (2005) (36)
- Maximizing the Retention of Antigen Specific Lymphocyte Function after Cryopreservation (2004) (35)
- The Invisible Arm of Immunity in Common Cancer Chemoprevention Agents (2013) (35)
- Peptide-Based Vaccines (2004) (34)
- T‐Cell Immunity to Oncogenic Proteins Including Mutated RAS and Chimeric BCR‐ABL a (1993) (34)
- Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce “danger signals” (2006) (34)
- Adoptive T cell therapy of solid cancers (2005) (33)
- MONITORING IMMUNE RESPONSES IN CANCER PATIENTS RECEIVING TUMOR VACCINES (2003) (31)
- HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers (2014) (30)
- Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine. (2001) (30)
- SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools - a compass in the land of biomarker discovery (2011) (30)
- Circulating Immune Complexes in Cystic Fibrosis and Their Correlation to Clinical Parameters (1986) (29)
- Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer. (2012) (29)
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer (2021) (28)
- Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer (2007) (27)
- Mining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancer (2014) (27)
- An analytical workflow for investigating cytokine profiles (2008) (27)
- Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force (2010) (27)
- Conflicts of interest in translational research (2004) (27)
- Induction of T cells specific for the mutated segment of oncogenic P21ras protein by immunization in vivo with the oncogenic protein. (1993) (27)
- Values in Translation: How Asking the Right Questions Can Move Translational Science Toward Greater Health Impact (2012) (27)
- Therapeutic cancer vaccines revamping: technology advancements and pitfalls (2021) (27)
- Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens. (2003) (26)
- AACR White Paper: Shaping the Future of Cancer Prevention – A Roadmap for Advancing Science and Public Health (2018) (26)
- Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo (2016) (26)
- Association between plasma diacetylspermine and tumor spermine synthase with outcome in triple negative breast cancer. (2019) (26)
- A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors (2016) (26)
- Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses (2007) (25)
- CCL21 and IFNγ recruit and activate tumor specific T cells in 3D scaffold model of breast cancer. (2014) (25)
- Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient. (2002) (25)
- Immunologic principles and immunotherapeutic approaches in ovarian cancer. (2003) (25)
- Death by Gun Violence-A Public Health Crisis. (2017) (25)
- Death by Gun Violence-A Public Health Crisis. (2017) (24)
- Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant. (2013) (24)
- Toward a stem cell gene therapy for breast cancer. (2009) (23)
- Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy. (2005) (23)
- Global role of the immune system in identifying cancer initiation and limiting disease progression. (2005) (23)
- Immunity to the HER-2/neu oncogenic protein. (1994) (22)
- Identification of Putative Immunologic Targets for Colon Cancer Prevention Based on Conserved Gene Upregulation from Preinvasive to Malignant Lesions (2013) (22)
- Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo (2016) (22)
- Immunomodulation of breast cancer via tumor antigen specific Th1. (2009) (22)
- Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity. (2003) (21)
- Current methods of epitope identification for cancer vaccine design. (2015) (21)
- Persistent immunity and survival after immunization with a HER2/neu (HER2) vaccine. (2016) (21)
- Therapeutic vaccines for ovarian cancer. (2013) (20)
- Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity. (2005) (20)
- Adoptive T-cell therapy for the treatment of solid tumours (2002) (20)
- Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer (2015) (20)
- Next generation approaches for tumor vaccination. (2017) (20)
- A plasma protein derived TGFβ signature is a prognostic indicator in triple negative breast cancer (2019) (20)
- Can Immunity to Breast Cancer Eliminate Residual Micrometastases? (2013) (19)
- Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors (2007) (19)
- Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. (2007) (19)
- Phase I studies of drug combinations. (2010) (19)
- Future directions in the management of ovarian cancer. (2003) (19)
- Immunotherapeutic Approaches for the Treatment of Breast Cancer (2004) (19)
- Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer (2016) (19)
- Antimetastatic gene expression profiles mediated by retinoic acid receptor beta 2 in MDA-MB-435 breast cancer cells (2005) (18)
- The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent (2015) (18)
- Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept. (2011) (18)
- SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art (2018) (18)
- Equity and the JAMA Network. (2021) (17)
- Laboratory analysis of T-cell immunity. (2006) (17)
- Expression of HLA-DP0401 Molecules for Identification of DP0401 Restricted Antigen Specific T Cells (2005) (17)
- The Antigenic Repertoire of Premalignant and High-Risk Lesions (2015) (17)
- Enhancing Cancer Vaccine Efficacy via Modulation of the Tumor Microenvironment (2009) (17)
- An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. (2008) (17)
- T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity (2013) (16)
- TLR8 ligation induces apoptosis of monocytic myeloid‐derived suppressor cells (2018) (16)
- Clinical translation of peptide-based vaccine trials: the HER-2/neu model. (2001) (16)
- Death by Gun Violence-A Public Health Crisis. (2017) (16)
- Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer (2017) (16)
- Clinical use of subcutaneous G-CSF or GM-CSF in malignancy. (2005) (15)
- Equity and the JAMA Network. (2021) (15)
- Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK (2013) (15)
- Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses (2022) (15)
- Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients (2002) (15)
- Functional T Cell Responses to Tumor Antigens in Breast Cancer Patients Have a Distinct Phenotype and Cytokine Signature1 (2007) (15)
- Immune modulation as a therapeutic strategy for non-small-cell lung cancer. (2008) (15)
- Preparedness of the CTSA's Structural and Scientific Assets to Support the Mission of the National Center for Advancing Translational Sciences (NCATS) (2012) (14)
- Antigen-specific recall urticaria to a peptide-based vaccine. (1999) (14)
- Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice (2014) (13)
- Tumor vaccines for the management of prostate cancer. (2000) (13)
- Expanding Assessments of Translational Research Programs (2014) (13)
- Peptide-based vaccines in breast cancer. (2004) (13)
- A Degenerate HLA-DR Epitope Pool of HER-2/neu Reveals a Novel In vivo Immunodominant Epitope, HER-2/neu88-102 (2010) (13)
- Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv–expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion (2006) (13)
- Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. (2017) (13)
- Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen (2009) (13)
- 2749 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity (2015) (12)
- Oncology and COVID-19. (2020) (12)
- Protein-bound polysaccharide-K induces IL-1β via TLR2 and NLRP3 inflammasome activation (2014) (12)
- Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity (2008) (12)
- Tumor-associated antigens identified early in mouse mammary tumor development can be effective vaccine targets. (2019) (12)
- Designing vaccines to prevent breast cancer recurrence or invasive disease. (2015) (11)
- Issues on clinical applications of cancer vaccines. (2001) (10)
- Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers (2006) (10)
- Immunity to WT 1 in the animal model and in patients with acute myeloid leukemia (2000) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens (2016) (10)
- A phase I trial of the safety and immunogenicity of a DNA-based vaccine encoding the HER2/neu (HER2) intracellular domain in subjects with HER2+ breast cancer. (2014) (9)
- Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models (2014) (9)
- Tumor stromal barriers to the success of adoptive T cell therapy (2007) (9)
- Phase 1b Trial of TLR8 Agonist VTX-2337 in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN) (2014) (9)
- Cellular immune parameters associated with improved long-term survival in advanced stage breast cancer patients after active immunization with a HER2-specific vaccine (2008) (9)
- Identification of Immunologic Biomarkers Associated with Clinical Response after Immune‐Based Therapy for Cancer (2009) (9)
- A phase I/II study of a HER2/neu (HER2) peptide vaccine plus concurrent trastuzumab. (2006) (8)
- Progress in the development of a therapeutic vaccine for breast cancer. (2010) (8)
- The Ultimate in Cancer Chemoprevention: Cancer Vaccines (2010) (8)
- Th1 epitope selection for clinically effective cancer vaccines (2014) (7)
- His-tag ELISA for the detection of humoral tumor-specific immunity (2004) (7)
- Antibodies to human tumor oncoproteins in cancer patients (2003) (7)
- Phase II Study of a HER-2/Neu (HER2) Intracellular Domain (ICD) Vaccine Given Concurrently with Trastuzumab in Patients with Newly Diagnosed Advanced Stage Breast Cancer. (2009) (7)
- Immunotherapy for breast cancer. (2017) (7)
- Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention (2021) (7)
- Pembrolizumab with low dose carboplatin for recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer-interim results. (2019) (6)
- Avelumab (MSB0010718C; anti-PD-L1) ± pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer: The phase III JAVELIN Ovarian 200 trial. (2016) (6)
- Breast cancer vaccines for treatment and prevention (2021) (6)
- HER-2/neu vaccines. (2003) (6)
- The Effect of Mouse Strain, Sex, and Carcinogen Dose on Toxicity and the Development of Lung Dysplasia and Squamous Cell Carcinomas in Mice (2019) (6)
- Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers (2020) (6)
- Multi-Epitope CTL Responses Induced by a Peptide Vaccine (EP-2101) in Colon and Non-Small Cell Lung Cancer Patients (2004) (6)
- Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates (2021) (6)
- Immunologic targets for breast cancer1 (2002) (6)
- Oncology and COVID-19 (2020) (6)
- A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients. (2004) (6)
- Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine. (2009) (6)
- Scholarly productivity and professional advancement of junior researchers receiving KL2, K23, or K08 awards at a large public research institution (2017) (5)
- Cancer vaccines for the treatment and prevention of non small-cell lung cancer. (2000) (5)
- Immunologic targets for breast cancer. (2002) (5)
- COX-2 inhibitors decrease expression of PD-L1 in colon tumors and increase the influx of Type I tumor infiltrating lymphocytes. (2022) (5)
- Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop (2019) (5)
- proliferation and synergistic antitumor response E s provides intratumoral T E T + s) combined with CD8 E cells (T T effector + Adoptive transfer of tumor-primed, in vitroactivated, CD4 (2008) (5)
- Preamble to the 2015 SITC immunotherapy biomarkers taskforce (2015) (5)
- Multimetric feature selection for analyzing multicategory outcomes of colorectal cancer: random forest and multinomial logistic regression models (2021) (5)
- Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients (2021) (4)
- HER2/neu peptide-based vaccines, with GM-CSF as an adjuvant, in patients with advanced-stage HER2/neu-expressing cancers. (2000) (4)
- HER2/neu (HER2) specific T-cell immunity in patients with HER2+ inflammatory breast cancer (IBC) and prognosis. (2009) (4)
- HER-2/neu protein (1997) (4)
- Movie Review of The Immortal Life of Henrietta Lacks. (2017) (4)
- Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial. (2022) (4)
- Death by Gun Violence-A Public Health Crisis. (2017) (4)
- Cancer Therapy : Preclinical VTX-2337 Is a Novel TLR 8 Agonist That Activates NK Cells and Augments ADCC (2012) (3)
- Phase I/II study of adoptive T-cell therapy following in vivo priming with a HER2/neu vaccine in patients with advanced-stage HER2+ breast cancer. (2014) (3)
- Increasing doses of cyclophosphamide suppress antigen-specific T helper-dependent immunity induced by a GM-CSF-secreting breast tumor vaccine (2008) (3)
- A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop (2021) (3)
- Toward a Breast Cancer Vaccine:Work in Progress (2003) (3)
- Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses (2021) (3)
- Underlying Autoimmune Disease Is Not a Contraindication to the Use of Ipilimumab. (2016) (3)
- Progress in ovarian cancer research: Proceedings of the 5th Biennial Ovarian Cancer Research Symposium (2005) (3)
- Death by Gun Violence-A Public Health Crisis. (2017) (3)
- Clinical Application of Plasmid-Based Cancer Vaccines (2013) (3)
- CD 4 + T-Cell Immunity to Mutated ras Protein in Pancreatic and Colon Cancer Patients 1 (2006) (3)
- Immuno-Oncology in the Era of Personalized Medicine. (2019) (3)
- Molecular targeting with cancer vaccines. (2005) (3)
- A phase I study of a DNA plasmid based vaccine encoding the HER2/neu (HER2) intracellular domain (ICD) in subjects with HER2+ breast cancer. (2009) (3)
- Equity and the JAMA Network. (2021) (2)
- Public Access to Scientific Research Findings and Principles of Biomedical Research-A New Policy for the JAMA Network. (2023) (2)
- Proteomic profiling of the autoimmune response to breast cancer antigens uncovers a suppressive effect of hormone therapy (2013) (2)
- Abstract OT3-1-02: Phase II randomized study of combination immunotherapy with or without Polysaccharide Krestin (PSK®) concurrently with a HER2 ICD peptide-based vaccine and trastuzumab in patients with stage IV breast cancer (2012) (2)
- Phase I study of intraperitoneal (IP) denileukin diftitox in patients with advanced ovarian cancer (OC) (2008) (2)
- Abstract 6593: PRGN-3005 UltraCAR-T™: multigenic CAR-T cells generated using non-viral gene delivery and rapid manufacturing process for the treatment of ovarian cancer (2020) (2)
- Abstract OT3-01-03: A phase I trial of the safety and immunogenicity of a DNA plasmid based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer (2017) (2)
- Erratum to: Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice (2016) (2)
- P1-13-04: Phase II Study of Topical Imiquimod and Abraxane for Treatment of Breast Cancer Cutaneous Metastases. (2011) (2)
- Vaccination targeting insulin-like growth factor binding protein-2 (IGFBP-2) in advanced ovarian cancer: Safety and immunogenicity. (2016) (2)
- Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer (2019) (2)
- Cancer Therapy : Preclinical Polysaccharide Krestin Is a Novel TLR 2 Agonist that Mediates Inhibition of Tumor Growth via Stimulation of CD 8 T Cells and NK Cells (2010) (2)
- Immunotherapy of Cancer (2006) (2)
- Death by Gun Violence-A Public Health Crisis. (2017) (2)
- Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting (2021) (2)
- Increasing the Efficiency and Quality of Clinical Research with Innovative Services and Informatics Tools (2013) (2)
- Evaluation of cancer immunity in mice. (2014) (2)
- Equity and the JAMA Network. (2021) (2)
- CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells (2014) (2)
- Antigen-Specific Cancer Vaccines (2003) (2)
- Final report and long-term outcomes: Phase I trial of a HER2 intracellular plasmid-based vaccine in HER2+ advanced stage breast cancer. (2021) (2)
- Death by Gun Violence-A Public Health Crisis. (2017) (2)
- Equity and the JAMA Network. (2021) (2)
- CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells (2015) (2)
- Scientific Integrity and Data Accuracy. (2019) (1)
- JAMA Oncology-The Year in Review, 2018. (2019) (1)
- Oncogenic proteins as tumor antigens Disis and Cheever 639 (2001) (1)
- Death by Gun Violence-A Public Health Crisis. (2017) (1)
- Death by Gun Violence-A Public Health Crisis. (2017) (1)
- Equity and the JAMA Network. (2021) (1)
- Equity and the JAMA Network. (2021) (1)
- Commentary on “Phase I Study of the BLP25 (MUC1 Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIB/IV Non–Small-Cell Lung Cancer” (2001) (1)
- Public Access to Scientific Research Findings and Principles of Biomedical Research-A New Policy for the JAMA Network. (2022) (1)
- Translational ResearchWorking Group Developmental Pathway for Immune ResponseModifiers (2008) (1)
- JAMA Oncology-The Year in Review, 2021. (2022) (1)
- Wouldn't We All Like to be a Little More LEAN? (2010) (1)
- Public Access to Scientific Research Findings and Principles of Biomedical Research-A New Policy for the JAMA Network. (2022) (1)
- JAMA Oncology-The Year in Review, 2019. (2020) (1)
- Public Access to Scientific Research Findings and Principles of Biomedical Research-A New Policy for the JAMA Network. (2022) (1)
- Equity and the JAMA Network. (2021) (1)
- Equity and the JAMA Network. (2021) (1)
- Public Access to Scientific Research Findings and Principles of Biomedical Research-A New Policy for the JAMA Network. (2022) (1)
- Trastuzumab-reactive antibodies (TR-abs) in serum and trastuzumab (Tzb) benefit prediction in patients with HER2-overexpressing breast cancer. (2012) (1)
- Death by Gun Violence-A Public Health Crisis. (2017) (1)
- Serum antibodies specific for tumor antigens in colorectal cancer may be useful diagnostic biomarkers. (2006) (1)
- Peptide-based tumor vaccines (2008) (1)
- Adjuvant Oophorectomy in the Treatment of Early-Stage BRCA Mutation-Positive Breast Cancer. (2015) (1)
- Abstract OT1-01-01: A phase I trial of the safety and immunogenicity of a multiple antigen vaccine (STEMVAC) in HER2 negative advanced stage breast cancer patients (2016) (1)
- The role of TLR2 in the immunostimulatory effect of Polysaccharide krestin (PSK) (41.13) (2009) (1)
- OT3-01-19: Phase II Study of Topical Imiquimod and Weekly Abraxane for the Treatment of Breast Cancer Cutaneous Metastases. (2011) (1)
- Breast cancer stem cell autoantibodies to identify women with advanced breast cancer. (2018) (1)
- Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: Clinical and immune responses. (2015) (1)
- Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy TLR2 Agonist PSK Activates Human NK Cells and Enhances the (2011) (1)
- Towards a stem cell gene therapy for breast cancer (2009) (1)
- Immunotherapy of glioblastoma multiforme (2003) (1)
- Immunologic Approaches to Breast Cancer Therapy (2018) (1)
- Micrometastases ? Can Immunity to Breast Cancer Eliminate Residual Updated (2013) (1)
- OT1-02-10: Phase I-II Study of HER2 Vaccination with Poly(I) • Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients. (2011) (1)
- enhanced antibody immunity The endogenous danger signal, crystalline uric acid, signals for (2008) (1)
- In vitro organotypic co-culture model for the study of bronchial epithelial clonal outgrowth during multistep lung tumorigenesis. (2004) (1)
- Vaccine targeting HIF1A in triple negative breast cancer (2014) (1)
- Abstract 3986: Protein-bound polysaccharide induces IL-1β via NLRP3 inflammasome activation. (2013) (1)
- Abstract 750: Identification of tumor antigens in transgenic mouse model as vaccine targets for the prevention of human breast cancer (2011) (0)
- Chapter 40 – Cancer – Solid Tumors (2005) (0)
- 546 A phase I dose escalation study of STEMVAC, a multi-antigen, multi-epitope Th1 selective plasmid-based vaccine, targeting stem cell associated proteins in patients with advanced breast cancer (2022) (0)
- 1177 Identification of and vaccination with antigen specific Th1 selective epitopes in bladder cancer: a step towards a multi-antigen vaccine for bladder cancer prevention (2022) (0)
- Abstract 747: Tumor vaccine adjuvant effect of TLR7 agonist Imiquimod is limited by inducing immusuppressive cells (2011) (0)
- Abstract 279: Bexarotene increases tumor CD8+ T cells and improves response to conventional breast chemotherapy in the transgenic mouse mammary tumor model TgMMTV-neu (2015) (0)
- Anti-Tumor Actions of Trametes Versicolor Extract Polysaccharide K Include Activation of Dendritic Cells and Gamma Delta T Cells (2013) (0)
- Induction of Therapeutic Breast Cancer Immunity With an IL-2 Immunotoxin (2005) (0)
- Abstract 273: TLR8 agonist VTX-2337 (motolimod) decreases monocytic myeloid-derived suppressor cells by inducing differentiation to mature antigen-presenting cells (2015) (0)
- F.132. T-Cell Cytokine Responses to Tumor-Associated Antigens in Breast Carcinoma Patients and Healthy Adults (2006) (0)
- Immunologic synergy between intermittent NSAID administration and antigen specific vaccination in inhibiting the development of intestinal polyps in the APC(Min/+) (2018) (0)
- 522 The ability of NSAIDs to inhibit polyp formation and stimulate Type I immunity is dose dependent (2015) (0)
- Abstract 3687: Bexarotene activates type 1 antigen presenting cells, increases tumor infiltrating CD8 T-cells, and augments the anti-tumor activity of chemotherapy in breast cancer (2017) (0)
- Public Access to Scientific Research Findings and Principles of Biomedical Research-A New Policy for the JAMA Network. (2022) (0)
- Abstract 4392: Vaccination targeting IGF-IR sensitizes tumors to tamoxifen therapy in an anti-estrogen resistant mouse model (2012) (0)
- Abstract P2-11-05: Overall survival in inflammatory breast cancer patients receiving Her-2 Neu directed tumor vaccine therapy: Matched comparison with SEER registry patients (2016) (0)
- Uric Acid Elicits Anti-Tumor Humoral Immunity Without T Cell Expansion When Used As A Vaccine Adjuvant (2005) (0)
- Abstract 2413: Preventing the development of breast cancer by immunizing with multi-antigen vaccines targeting breast cancer proteins (2010) (0)
- Abstract PD3-08: Modulation of immunity with 2-fluorofucose (2FF) for breast cancer treatment and prevention (2016) (0)
- Culture conditions promoting innate immunity and homeostatic proliferation generate highly enriched, MUC1- or HER2/neu-specific CD4+ and CD8+ T cells (P4419) (2013) (0)
- TLR7 agonist imiquimod is a potent vaccine adjuvant (2008) (0)
- A Phase I/II trial of HER-2/neu vaccine primed autologous T-cell infusions in patients with treatment refractory HER-2/neu overexpressing breast cancer. (2023) (0)
- Abstract 623: Identifying candidate antigens for a ductal carcinomain situvaccine that are essential to breast cancer survival across multiple subtypes (2017) (0)
- Use Of Genetic Adjuvants Encoding GM-CSF And IL-12 On Conditioning The Immunization Site And Improving The Efficacy Of Non Small Cell Lung Cancer DNA Based Vaccines (2010) (0)
- Abstract P2-09-04: Anti-Trastuzumab Antibodies Are Associated with Longer Progression Free Survival in Patients Treated with Trastuzumab (2010) (0)
- Phase II Study of a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide-Based Vaccine Administered to Stage IIIB and IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab Monotherapy (2008) (0)
- PROTEOMICS – Clinical Applications Table of Contents (2013) (0)
- Serum antibodies recognizing hypoxia-inducible factor 1-alpha and platinum sensitivity in ovarian cancer (2014) (0)
- The Impact of National Press Coverage on Early Phase Clinical Trial Recruitment and Enrollment. (2009) (0)
- OT2-05-05: Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming with a HER2 Peptide-Based Vaccine in Patients with Stage IV Breast Cancer. (2011) (0)
- Cancer Therapy : Preclinical Dendritic Cell – Activating Vaccine Adjuvants Differ in the Ability to Elicit Antitumor Immunity Due to an Adjuvant-Speci fi c Induction of Immunosuppressive Cells (2012) (0)
- Abstract 1806: TLR2 agonist PSK activates NK cells and enhances the anti-tumor effect of HER2-targeted monoclonal antibody therapy (2011) (0)
- Up Close and Personal with Cancer (2013) (0)
- Vaccine targeting antigens associated with cancer stem cells/epithelial to mesenchymal transition inhibits triple negative breast cancer growth (2018) (0)
- Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report (2021) (0)
- Abstract 1556: Retinoid X receptor agonists enhances Th1 antigen-specific and polyfunctional T cells with the HER2-IGFBP2-IGF1R vaccine (2021) (0)
- Abstract 1352: Identifying pre-diagnostic breast cancer antigens in transgenic mouse mammary tumor models for preventative vaccine development (2015) (0)
- General Approaches to Measuring Immune Responses (2007) (0)
- Abstract IA27: Immunomodulation of breast cancer (2013) (0)
- Optimizing a multi cancer antigen plasmid-based vaccine using an in situ prediction model. (2022) (0)
- Persistent immunity after therapeutic vaccination targeting HER2/neu correlated with post-vaccination magnitude of interferon gamma Elispot responses (2014) (0)
- Erratum to: Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce “danger signals” (2006) (0)
- Sources of referral to early phase clinical trials: a case for putting all your eggs in one basket. (2009) (0)
- Characterization of colon cancer-associated antigens that would be key therapeutic targets in the prevention of disease relapse or progression. (2012) (0)
- INHIBITING OF INFLAMMATORY MEDIATORS Role of COX-2 Inhibition in the Treatment of Metastatic Breast Cancer (2004) (0)
- Abstract 2742: Identification of tumor antigens in neu transgenic mice may provide biomarkers useful for the early detection and diagnosis of human breast cancer (2010) (0)
- TLR8 agonist VTX-2337 enhances NKG2D-mediated cytotoxicity of NK cells (2013) (0)
- Phase 1 study of infusion of HER-2/neu specific T cells in patients with advanced stage HER-2/neu overexpressing cancers who have received a HER-2/neu vaccine (41.3) (2009) (0)
- Abstract P2-15-02: The efficacy of recruitment and retention strategies for research subjects in an early phase investigator-initiated breast cancer trial. (2012) (0)
- Distinct Phenotype and Cytokine Signature Antigens in Breast Cancer Patients Have a Functional T Cell Responses to Tumor (2007) (0)
- Abstract ES6-1: Immunotherapeutic approaches to breast cancer (2015) (0)
- Abstract P2-02-02: Phase I trial of the safety and immunogenicity of a tri-antigen vaccine targeting HER2, IGFBP-2, and IGF-IR in patients with non-metastatic breast cancer (2023) (0)
- Serum antibodies recognizing BRCA1 at time of diagnosis and primary platinum resistance in ovarian cancer (2014) (0)
- Abstract 1266: Downregulation of PD-L1 by NSAID administration augments the effects of a multi-antigen vaccine for the prevention of adenomatous polyps in APC(Min/+) mice (2018) (0)
- The Level of HER-2/neu Protein Expression in Primary Breast Cancer May Impact the Development of HER-2/neu Specific Humoral Immunity (2004) (0)
- A phase I trial of a DNA plasmid-based vaccine targeting insulin-like growth factor binding protein-2 (IGFBP-2) in patients with advanced ovarian cancer: Preliminary safety and immunogenicity (2014) (0)
- Abstract P5-04-06: Oral immunomodulatory agents prevent tumor growth and increase tumor CD8 T cell infiltrate; bexarotene further improves tumor response to conventional chemotherapy in breast tumors (2015) (0)
- Phase I-II Study of Denileukin Diftitox (ONTAK®) in Patients with Advanced Refractory Breast Cancer. (2009) (0)
- Room 501 A-C, Los Angeles Convention Center Epidemiology 11 Inflammation, Immunity, and Novel Pathways (2007) (0)
- Abstract 5112: Immune biomarkers of clinical response after NSAID treatment in combination with vaccination targeting EGFR-COX2-CDC25B in the APC(Min/+) mouse model (2023) (0)
- 10th Biennial Helene Harris Memorial Trust meeting. (2006) (0)
- Abstract 2401: IGF-IR peptide vaccine inhibits tumor growth via IFN-g-dependent biologic remodeling of the tumor (2010) (0)
- Abstract 748: TLR3 agonist Ampligen® as an adjuvant inhibits the growth of breast cancer (2011) (0)
- Chemical carcinogens used to induce spontaneous tumors may suppress tumor specific T-cell immunity (2013) (0)
- Association of the level of HER2/neu (HER2) gene amplification in breast cancer and the magnitude of antigen specific T-cell immunity achieved after HER2 vaccination. (2009) (0)
- Abstract 2415: Evaluation of a DNA vaccine and adjuvant construct for producing anti tumor immunity targeting IGFBP2 (2010) (0)
- Regulatory T Cells May Induce Tolerance Early in the Course of Tumor Development (2004) (0)
- Mining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancer (2013) (0)
- Abstract 3380: Seven autoantibody panel, validated in two independent patient serum collections, can detect women with DCIS and invasive breast cancer (2022) (0)
- Abstract 2224: Panel of autoantibodies to seven early tumor-associated overexpressed proteins can identify women with DCIS from women with benign breast tumors detected by mammography (2018) (0)
- Patient specific characteristics associated with T-cell expansion for HER2/neu vaccine-primed autologous adoptive T-cell therapy. (2018) (0)
- 1176 Optimizing immunization schedules for therapeutic vaccination (2022) (0)
- Mining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancer (2014) (0)
- Level of HER-2/neu protein expression in primary breast cancer may impact the development of HER-2/neu-specific endogenous immunity (2005) (0)
- Abstract 2683: Identification of tumor antigens in neu transgenic mice as diagnostic targets for the early detection of human breast cancer (2011) (0)
- 549 Booster vaccination of a HER2 helper T-cell vaccine increased HER2 immunity in metastatic HER2 positive breast cancer. (2022) (0)
- Abstract CN01-01: Vaccines to prevent breast cancer (2013) (0)
- Abstract CN04-01: Multi-antigen vaccines for cancer prevention (2015) (0)
- Abstract 1571: Developing antigen-specific Th1 epitope based vaccines by excluding immunosuppressive peptide sequences (2012) (0)
- Abstract 1184: Comprehensive analysis with interactive exploration of immune response signatures in 10,000 tumor samples (2019) (0)
- Abstract AP28: ANTITUMOR RESPONSE AFTER VACCINATION TARGETING INSULIN GROWTH FACTOR BINDING PROTEIN 2 IN A SYNGENEIC MOUSE MODEL OF OVARIAN CANCER LOCALIZED BY THREE-DIMENSIONAL IN VIVO OPTICAL IMAGING (2019) (0)
- JAMA Oncology-The Year in Review, 2022. (2023) (0)
- Abstract NTOC-097: VACCINATION TARGETING INSULIN–LIKE GROWTH FACTOR BINDING PROTEIN–2 (IGFBP–2) IN ADVANCED OVARIAN CANCER: SAFETY, IMMUNOGENICITY, AND SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) COMPARISON (2017) (0)
- Identification of Tumor Rejection Antigens for Breast Cancer Using a Mouse Tumor Rejection Model (2008) (0)
- Immunologic endpoints in vaccine development (2001) (0)
- leukemia Immunity to WT1 in the animal model and in patients with acute myeloid (2010) (0)
- CMV Antibody Immunity as a Predictor of a CMV-Specific Cellular Immune Response (2004) (0)
- Current topics in ovarian cancer (2003) (0)
- Issues on Clinical Applications of Cancer Vaccines. (2001) (0)
- Motolimod, a selective TLR8 agonist induces apoptosis in monocytic myeloid-derived suppressor cells (M-MDSC) (2015) (0)
- Equity and the JAMA Network. (2021) (0)
- Immunization with homologous foreign proteins generates immunity against "self tumor antigens (1996) (0)
- Unexpected Liver and Kidney Pathology in C57BL/6J Mice Fed a High-fat Diet and Given Azoxymethane to Induce Colon Cancer. (2022) (0)
- Public Access to Scientific Research Findings and Principles of Biomedical Research-A New Policy for the JAMA Network. (2022) (0)
- Precision analysis of a whole blood T cell subset immunophenotyping assay (2013) (0)
- Abstract A32: Identification and characterization of colon cancer-associated antigens (2010) (0)
- Clinical Studies of Vaccines Targeting Breast Cancer 1 (2003) (0)
- 1308 Bacteria specific IL-10 secreting T-cells derived from the gut are cross-reactive with tumor antigens and accelerate tumor growth in mouse models (2022) (0)
- Use of the TLR2 ligand polysaccharide krestin to maximize conventional cancer therapy (2017) (0)
- Crafting a JAMA Oncology Clinical Challenge. (2019) (0)
- Abstract SY24-03: Vaccines for the prevention of cancer (2011) (0)
- Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer (2016) (0)
- intracellular domain of HER- 2 / neu for the prevention or treatment of malignancies. (1996) (0)
- Abstract 523: γα T cells are activated by protein-bound polysaccharide krestin (PSK) and contribute to the antitumor effect of PSK (2012) (0)
- Abstract 4774: Identification and characterization of colon cancer associated antigens which would be key therapeutic targets in the prevention of disease relapse or progression (2010) (0)
- DISEASES of the BREAST Update on Breast Cancer Vaccines (0)
- Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancer (2022) (0)
- The Lasker Awards--Recognizing and Highlighting Oncology Research. (2015) (0)
- Public Access to Scientific Research Findings and Principles of Biomedical Research-A New Policy for the JAMA Network. (2022) (0)
- Translational Oncology: Transforming Cancer Care (2007) (0)
- CITN11-02 phase I trial of subcutaneous recombinant human IL-15 (rhIL-15) is associated with expansion of circulating CD56+ NK cells and CD8+ T cells (2016) (0)
- Thank You JAMA Oncology Authors, Peer Reviewers, and Readers. (2016) (0)
- A phase I dose-escalation trial of alpha-tocopheryloxyacetic acid and concurrent trastuzumab in patients with treatment refractory HER2+ metastatic breast cancer. (2020) (0)
- NaturallyOccurringProstateCancerAntigen- SpecificT CellResponsesofaTh1PhenotypeCanBe DetectedinPatientsWithProstateCancer (2001) (0)
- Vaccination with pre-diagnostic tumor antigens but not established tumor antigens inhibits spontaneous tumorigenesis in TgMMTV-neu mice (2013) (0)
- Public Access to Scientific Research Findings and Principles of Biomedical Research-A New Policy for the JAMA Network. (2022) (0)
- Phase II study of neoadjuvant IGFBP-2 vaccination with neoadjuvant carboplatin and paclitaxel in advanced ovarian cancer. (2018) (0)
- JAMA Oncology-The Year in Review, 2020. (2021) (0)
- Public Access to Scientific Research Findings and Principles of Biomedical Research-A New Policy for the JAMA Network. (2022) (0)
- Preliminary validation of nCounter PanCancer immune profiling of FFPE slides and pbmc in CITN-05, a CITN study of the immunological effects of an IDO1 inhibitor in patients with ovarian carcinoma (2015) (0)
- Peptide Vaccines for Cancer Treatment (2006) (0)
- Abstract P5-16-04: A phase I study of a DNA plasmid based vaccine encoding the HER-2/neu intracellular domain in subjects with HER2+ breast cancer. (2012) (0)
- Effect of Cryopreservation on Assays of Antigen-Specific T Cells: Comparison of Tetramer, Cytokine Flow Cytometry, and ELISPOT (2004) (0)
- 2011 Multi-antigen vaccination for colon cancer treatment and prevention (2015) (0)
- Abstract OT1-16-01: A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2 positive breast cancer (2022) (0)
- Abstract IA016: Vaccine approach for the interception of colon cancer (2023) (0)
- Immunologic Monitoring in Immuno‐Oncology (2018) (0)
- Optimization of ex vivo expansion of HER2 specific polyfunctional Th1/Th17 cells from HER2 vaccine primed PBMC (2013) (0)
- Study of HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab. Phase 2 (2009) (0)
- Immunity to HER-1/neu Protein (1998) (0)
- Immunoediting of tumors results in broad phenotypic changes including loss of immune recognition, altered response to therapy, and reduced differentiation (2005) (0)
- 1–33 Fusion Cell Vaccination of Patients With Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses (2005) (0)
- If we build it they will come: targeting the immune response to breast cancer (2019) (0)
- Final results of a phase II trial of weekly nab-paclitaxel with GM-CSF as chemoimmunotherapy for platinum-resistant epithelial ovarian cancer. (2012) (0)
- Public Access to Scientific Research Findings and Principles of Biomedical Research-A New Policy for the JAMA Network. (2022) (0)
- A34 Identification of Th1 Epitopes in Lung Non-Small Cell Lung Cancer Antigens to Develop a Multiantigen Vaccine (2020) (0)
- Enhancing HER2/neu Specific T-cell Therapy by Targeting the Tumor Endothelium (41.11) (2009) (0)
- Equity and the JAMA Network. (2021) (0)
- Death by Gun Violence-A Public Health Crisis. (2017) (0)
- Equity and the JAMA Network. (2021) (0)
- Abstract PD12-05: PD12-05 Adipocyte directed vaccination to reduce the risk of breast cancer (2023) (0)
- Mac Cheever (1944–2021): a tribute to a life of achievement and service (2022) (0)
- Public Access to Scientific Research Findings and Principles of Biomedical Research-A New Policy for the JAMA Network. (2022) (0)
- Equity and the JAMA Network. (2021) (0)
- ' s response to reviews Antimetastatic gene expression profiles mediated by retinoic acid receptor beta 2 in MDA-MB-435 Title : breast cancer cells (2005) (0)
- Mary L. (Nora) Disis, MD: Ready to become editor in chief of the new JAMA Oncology. (2015) (0)
- A Call for Viewpoints (2015) (0)
- Performance characteristics of common immunologic biomarkers used in clinical trials. (2006) (0)
- Death by Gun Violence-A Public Health Crisis. (2017) (0)
- JAMA Oncology-The Year in Review, 2016. (2017) (0)
- Preventing the Development of Breast Cancer by Immunizing with Multi-Antigen Vaccines Targeting Proteins Associated with Oncogenesis. (2009) (0)
- Micrometastases?Immunity to Breast Cancer Eliminate Residual (2014) (0)
- JAMA Oncology-The Year in Review, 2017. (2018) (0)
- munotherapy in Stage IIIB/IV Non-Small-Cell Lung Cancer" (2001) (0)
- Abstract 286: Coordinated activation of TLR8 and NLRP3 by VTX-2337 (motolimod) ignites tumoricidal NK cell activity (2015) (0)
- Ex Vivo Expansion of HER2-Specific T Cells for the Treatment of HER2-Overexpressing Breast Cancer (2002) (0)
- Approaches to In Vivo Imaging of Cancer Immunotherapy (2006) (0)
- Public Access to Scientific Research Findings and Principles of Biomedical Research-A New Policy for the JAMA Network. (2022) (0)
- Data Analysis Protocols for Identifying Cytokine Signatures in Breast Cancer and Type 1 Diabetes (2007) (0)
- Phase II Study of HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab (2010) (0)
- Announcing JAMA Oncology. (2015) (0)
- Abstract C220: Characterization of potential immunologic targets found in both mice and man that are expressed in colon adenomas and colorectal cancer. (2011) (0)
- Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+ breast cancer murine model (2022) (0)
- Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients (2021) (0)
- Augments ADCC VTX-2337 Is a Novel TLR 8 Agonist That Activates NK Cells and Updated (2012) (0)
- Abstract KP03: NOVEL IMMUNOTHERAPEUTICS FOR OVARIAN CANCER (2017) (0)
- Adjuvant Effect of Topical Imiquimod Compared to Intradermal GM-CSF on the Cellular Composition of Draining Lymph Nodes (2004) (0)
- AWARD NUMBER: W81XWH-07-1-0525 TITLE: CD8 T Cells and Immunoediting of Breast Cancer PRINCIPAL INVESTIGATOR: Keith L. Knutson CONTRACTING ORGANIZATION: Mayo Clinic (2009) (0)
- Abstract PR007: Candidate antigens for a ductal carcinoma in situ vaccine, essential for breast cancer cell survival across multiple subtypes, are immunogenic in DCIS and IBC (2022) (0)
- Abstract 2681: Identification of potential immunologic targets found in mice and man that are expressed in colon adenomas and colorectal cancer (2011) (0)
- Abstract A33: Identification of potential immunologic targets in mice and man that are overexpressed in colon adenomas and colorectal cancer (2010) (0)
- Abstract POSTER-TECH-1107: Primary platinum sensitivity in ovarian cancer and serum antibodies recognizing hypoxia-inducible factor 1-alpha and p53 (2015) (0)
- Abstract P5-01-09: Early tumor antigens discovered in TgMMTV-neu mice may provide targets for early breast cancer diagnosis and prevention (2013) (0)
- Abstract 3135: HER2 specific adoptive T cells shown to localize and infiltrate all sites of disease using combined SPECT and PET imaging (2015) (0)
- Abstract P2-05-03: Role of tumor immune environment in tumor initiation and growth rates in mouse mammary tumor models (2013) (0)
This paper list is powered by the following services:
Other Resources About Mary L. Disis
What Schools Are Affiliated With Mary L. Disis?
Mary L. Disis is affiliated with the following schools:
